Your browser doesn't support javascript.
loading
Transparency in drug regulation: public assessment reports in Europe and Australia.
Papathanasiou, Peter; Brassart, Laurent; Blake, Paul; Hart, Anna; Whitbread, Lel; Pembrey, Richard; Kieffer, Jill.
Afiliação
  • Papathanasiou P; Therapeutic Goods Administration, Regulatory Services Group, Department of Health, 136 Narrabundah Lane, Symonston, ACT 2609, Australia. Electronic address: peter.papathanasiou@gmail.com.
  • Brassart L; European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5 EU, UK.
  • Blake P; European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5 EU, UK.
  • Hart A; Therapeutic Goods Administration, Regulatory Services Group, Department of Health, 136 Narrabundah Lane, Symonston, ACT 2609, Australia.
  • Whitbread L; Therapeutic Goods Administration, Regulatory Services Group, Department of Health, 136 Narrabundah Lane, Symonston, ACT 2609, Australia.
  • Pembrey R; Therapeutic Goods Administration, Regulatory Services Group, Department of Health, 136 Narrabundah Lane, Symonston, ACT 2609, Australia.
  • Kieffer J; European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5 EU, UK. Electronic address: jill.kieffer@ema.europa.eu.
Drug Discov Today ; 21(11): 1806-1813, 2016 11.
Article em En | MEDLINE | ID: mdl-27373773
ABSTRACT
Openness and transparency are important considerations for medicines regulators, where public health is of paramount concern. As part of their commitment to transparency, the European Medicines Agency (EMA) and Therapeutic Goods Administration (TGA) in Australia publish information relating to their evaluation of medicines via public assessment reports. European Public Assessment Reports (EPARs) and Australian Public Assessment Reports (AusPARs) provide information about the considerations that led the regulator to approve or refuse the application. The reports summarise assessments by each regulator of the information provided on the quality, safety, and efficacy of the medicine under evaluation. Here, we describe the experiences of two established medicines regulators in publishing public assessment reports, and reflect on their future role in communicating medicines information.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Participação da Comunidade / Controle de Medicamentos e Entorpecentes Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Participação da Comunidade / Controle de Medicamentos e Entorpecentes Idioma: En Ano de publicação: 2016 Tipo de documento: Article